Combined modality management of breast cancer: Development of predictive markers through proteomics

被引:14
作者
Chakravarthy, B
Pietenpol, JA
机构
[1] Vanderbilt Univ, Med Ctr, Dept Radiat Oncol, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Med Ctr, Dept Biochem, Nashville, TN 37232 USA
关键词
D O I
10.1016/S0093-7754(03)00267-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The treatment of localized breast cancer often requires the use of surgery, radiation, and chemotherapy. The optimal sequencing of these treatments remains controversial. Although randomized studies have not found an improvement in survival with the use of neoadjuvant chemotherapy, a higher percentage of patients can undergo breast conservation. This clinical setting also allows us the unique opportunity to measure in vivo response to a select drug or drug combination. While there have been many retrospective studies looking at prognostic markers of response, there have been very few prospective studies developing markers that predict ultimate outcome from a specific drug or drug combination. This review discusses some of the newer technologies being used to develop predictive markers of therapeutic response. Proteomics is the study of the complete set of proteins expressed in a cell. It is a powerful tool to compare two different samples. Serial biopsies that compare the protein profile before and 24 hours after a cycle of chemotherapy may allow us to determine particular protein profiles that predict for ultimate clinical outcome. © 2003 Elsevier Inc. All rights reserved.
引用
收藏
页码:23 / 36
页数:14
相关论文
共 103 条
[1]   Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; Clinical experience and parameters predicting outcome [J].
Aas, T ;
Geisler, S ;
Paulsen, T ;
BorresenDale, AL ;
Varhaug, JE ;
Lonning, PE ;
Akslen, LA .
ACTA ONCOLOGICA, 1996, 35 (05) :5-8
[2]   Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling [J].
Alizadeh, AA ;
Eisen, MB ;
Davis, RE ;
Ma, C ;
Lossos, IS ;
Rosenwald, A ;
Boldrick, JG ;
Sabet, H ;
Tran, T ;
Yu, X ;
Powell, JI ;
Yang, LM ;
Marti, GE ;
Moore, T ;
Hudson, J ;
Lu, LS ;
Lewis, DB ;
Tibshirani, R ;
Sherlock, G ;
Chan, WC ;
Greiner, TC ;
Weisenburger, DD ;
Armitage, JO ;
Warnke, R ;
Levy, R ;
Wilson, W ;
Grever, MR ;
Byrd, JC ;
Botstein, D ;
Brown, PO ;
Staudt, LM .
NATURE, 2000, 403 (6769) :503-511
[3]   HER-2/NEU IN NODE-NEGATIVE BREAST-CANCER - PROGNOSTIC-SIGNIFICANCE OF OVEREXPRESSION INFLUENCED BY THE PRESENCE OF INSITU CARCINOMA [J].
ALLRED, DC ;
CLARK, GM ;
TANDON, AK ;
MOLINA, R ;
TORMEY, DC ;
OSBORNE, CK ;
GILCHRIST, KW ;
MANSOUR, EG ;
ABELOFF, M ;
EUDEY, L ;
MCGUIRE, WL .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (04) :599-605
[4]   ASSOCIATION OF P53 PROTEIN EXPRESSION WITH TUMOR-CELL PROLIFERATION RATE AND CLINICAL OUTCOME IN NODE-NEGATIVE BREAST-CANCER [J].
ALLRED, DC ;
CLARK, GM ;
ELLEDGE, R ;
FUQUA, SAW ;
BROWN, RW ;
CHAMNESS, GC ;
OSBORNE, CK ;
MCGUIRE, WL .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (03) :200-206
[5]   Phase II study of weekly intravenous recombinant humanized Anti-p185(HER2) monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast [J].
Baselga, J ;
Tripathy, D ;
Mendelsohn, J ;
Baughman, S ;
Benz, CC ;
Dantis, L ;
Sklarin, NT ;
Seidman, AD ;
Hudis, CA ;
Moore, J ;
Rosen, PP ;
Twaddell, T ;
Henderson, IC ;
Norton, L .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) :737-744
[6]   HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer [J].
Berry, DA ;
Muss, HB ;
Thor, AD ;
Dressler, L ;
Liu, ET ;
Broadwater, G ;
Budman, DR ;
Henderson, IC ;
Barcos, M ;
Hayes, D ;
Norton, L .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (20) :3471-3479
[7]  
BIANCO AR, 2000, P AN M AM SOC CLIN, V19, pA75
[8]  
Blichert-Toft M, 1992, J Natl Cancer Inst Monogr, P19
[9]   Primary chemotherapy in operable breast cancer: Eight-year experience at the Milan Cancer Institute [J].
Bonadonna, G ;
Valagussa, P ;
Brambilla, C ;
Ferrari, L ;
Moliterni, A ;
Terenziani, M ;
Zambetti, M .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (01) :93-100
[10]   Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation [J].
Buchholz, TA ;
Tucker, SL ;
Masullo, L ;
Kuerer, HM ;
Erwin, J ;
Salas, J ;
Frye, D ;
Strom, EA ;
McNeese, MD ;
Perkins, G ;
Katz, A ;
Singletary, SE ;
Hunt, KK ;
Buzdar, AU ;
Hortobagyi, GN .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) :17-23